# Moleculin Biotech, Inc.

Type: Company (MBRX)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/moleculin-biotech-inc
Canonical HTML page: https://getfinancebrief.com/entity/moleculin-biotech-inc

## Recent coverage (1 stories)

### MBRX Down 97% to $0.57 Despite EPS Beat: $22 Target Stale?
2026-08-17 00:56:51 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Full story: https://getfinancebrief.com/story/mbrx-down-97-percent-eps-beat-22-target-stale

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.